RT info:eu-repo/semantics/article
T1 Evaluation of cytokines as robust diagnostic biomarkers for COVID-19 detection
A1 Tamayo Velasco, Álvaro
A1 Peñarrubia Ponce, María Jesús
A1 Álvarez González, Francisco Javier
A1 Gonzalo Benito, Hugo
A1 Fuente, Ignacio de la
A1 Martín Fernández, Marta
A1 Eiros Bouza, José María
A1 Martínez de Paz, Pedro José
A1 Miramontes González, José Pablo
A1 Fiz López, Aida
A1 Arribas Rodríguez, Elisa
A1 Cal Sabater, Paloma de la
A1 Aller de la Fuente, Rocío
A1 Dueñas Gutiérrez, Carlos Jesús
A1 Heredia Rodríguez, María
A1 Tamayo Gómez, Eduardo
A1 Bernardo Ordiz, David
A1 Gómez Sánchez, Esther
K1 COVID-19 (Enfermedad)
K1 Diagnosis
K1 Diagnóstico
K1 Biomarkers
K1 Biomarcadores
AB Antigen tests or polymerase chain reaction (PCR) amplification are currently COVID-19 diagnostic tools. However, developing complementary diagnosis tools is mandatory. Thus, we performed a plasma cytokine array in COVID-19 patients to identify novel diagnostic biomarkers. A discovery–validation study in two independent prospective cohorts was performed. The discovery cohort included 136 COVID-19 and non-COVID-19 patients recruited consecutively from 24 March to 11 April 2020. Forty-five cytokines’ quantification by the MAGPIX system (Luminex Corp., Austin, TX, USA) was performed in plasma samples. The validation cohort included 117 patients recruited consecutively from 15 to 25 April 2020 for validating results by ELISA. COVID-19 patients showed different levels of multiple cytokines compared to non-COVID-19 patients. A single chemokine, IP-10, accurately identified COVID-19 patients who required hospital admission (AUC: 0.962; 95%CI (0.933–0.992); p < 0.001)). The results were validated in an independent cohort by multivariable analysis (OR: 25.573; 95%CI (8.127–80.469); p < 0.001) and AUROC (AUC: 0.900; 95%CI (0.846–0.954); p < 0.001). Moreover, showing IP-10 plasma levels over 173.35 pg/mL identified COVID-19 with higher sensitivity (86.20%) than the first SARS-CoV-2 PCR. Our discover–validation study identified IP-10 as a robust biomarker in clinical practice for COVID-19 diagnosis at hospital. Therefore, IP-10 could be used as a complementary tool in clinical practice, especially in emergency departments.
PB MDPI
SN 2075-4426
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/51604
UL https://uvadoc.uva.es/handle/10324/51604
LA eng
NO Journal of Personalized Medicine, 2021, vol. 11, n. 7, 681
NO Producción Científica
DS UVaDOC
RD 19-oct-2024